HilleVax, Inc. (HLVX)

Market Cap	93.97M
Revenue (ttm)	n/a
Net Income (ttm)	-143.51M
Shares Out	49.72M
EPS (ttm)	-3.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	602,783
Open	1.890
Previous Close	1.870
Day's Range	1.880 - 1.950
52-Week Range	1.550 - 20.220
Beta	0.79
Analysts	Hold
Price Target	2.50 (+32.28%)
Earnings Date	Aug 12, 2024

About HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 90
• Stock Exchange: NASDAQ
• Ticker Symbol: HLVX

Analyst Forecast

According to 5 analysts, the average rating for HLVX stock is "Hold." The 12-month stock price forecast is $2.5, which is an increase of 32.28% from the latest price.

Price Target

$2.5

(32.28% upside)

Analyst Consensus: Hold